🔴 Milestone Pharmaceuticals is trading 5.4% down today with no clear company-specific negative catalyst

Milestone Pharmaceuticals is trading 5.4% lower at $0.75, with no clear company-specific negative catalyst identified for September 25, 2026.

• Shares fell from $0.79 on September 24 and $0.86 on September 23.
• The latest announcement was positive but routine: enrollment of the first Canadian participant in its ReVeRA-301 Phase 3 trial.
• Broader markets are mixed, so the decline is not clearly explained by sector or index-wide selling.